Collagenase clostridium histolyticum is under clinical development by Endo International and currently in Phase II for Fasciitis. According to GlobalData, Phase II drugs for Fasciitis does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Collagenase clostridium histolyticum LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Collagenase clostridium histolyticum overview

Collagenase Clostridium histolyticum (Xiapex, Xiaflex) contains purified collagenase Clostridium histolyticum, consisting of two microbial collagenases namely collagenase AUX-I and collagenase AUX-II. It is formulated as lyophilized powder for solution, injection for intralesional route of administration. Xiaflex is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord,  for the treatment of adult men with Peyronie’s  disease with a palpable  plaque and curvature deformity of at least 30 degrees at the start of therapy. Xiapex also indicated for the treatment of two Dupuytren's contracture (DC) cords concurrently.

Collagenase Clostridium histolyticum is under development for the treatment of plantar fasciitis, benign tumor, cellulite and human lipoma lateral thigh fat, plantar fibromatosis (unspecified musculoskeletal disorders), arthrofibrosis of the knee post knee arthroplasty and unspecified indications. The drug candidate is administered through subcutaneous route. It acts by targeting collagen.

The drug candidate was under development for the treatment of frozen shoulder syndrome and uterine fibroids, 

Endo International overview

Endo International (Endo) is a specialty healthcare company that develops, manufactures and commercializes various branded pharmaceuticals, generic pharmaceuticals, sterile injectables and other products through its operating companies. It sells generic products in the US in various categories including urology, pain management, orthopedics, endocrinology, central nervous system (CNS) disorders, cancer, cardiovascular diseases, and women’s health. The company offers branded pharmaceuticals for conditions related to urology, orthopedics, endocrine disorders, and pain management. Endo also provides over the counter (OTC) products, which include dermatological products and anti-infectives. The company sells its products through independent wholesale distributors to retailers, government agencies, doctors, clinics, independent retail and specialty pharmacies and independent specialty distributors. Endo is headquartered in Dublin, Ireland.

For a complete picture of Collagenase clostridium histolyticum’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.